Taiwan Liposome Company (TLC)

55 articles with Taiwan Liposome Company (TLC)

• TLC Reports Third Quarter 2020 Financial Results and Provides Business Update

  10/28/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the third quarter ending September 30, 2020, and provided a business update.

• TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer

  10/21/2020

  TLC, a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the appointment of Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development.

• TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)

  10/14/2020

  TLC announced that the first subject has been enrolled in the Phase I clinical trial of TLC19 for treatment or prophylaxis of Coronavirus disease 2019.

• TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19Dual government support in streamlined development of anti-COVID-19 therapy

  10/7/2020

  TLC announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee in Australia for the Company’s Phase I clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension for Coronavirus disease 2019.

• TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

  9/21/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET.

• TLC to Present at Cantor Virtual Global Healthcare Conference - Sep 11, 2020

  9/11/2020

  TLC announced that George Yeh, President of TLC, will be discussing recent activities regarding the company in a fireside chat with Kristen Kluska, Research Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00am ET.

• TLC to Present at HC Wainwright & Co. 22nd Annual Global Investment Conference

  9/9/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET.

• TLC to Present at Baird’s 2020 Global Healthcare Conference

  9/3/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET.

• TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China

  8/26/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in conjunction with 3SBio, announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted its Marketing Authorization Application for Ampholipad™, TLC’s complex generic of Gilead’s AmBisome® used for the treatment of systemic fungal infections.

• TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19

  8/14/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the submission of an Investigational New Drug Application to the Taiwan Food and Drug Administration for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus disease 2019.

• TLC Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/5/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the second quarter ending June 30, 2020, and provided a business update.

• Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19

  7/15/2020

  Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities

• TLC Announces Completion of US$23 Million Financing

  6/30/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2020 cash capital offering of ordinary shares in Taiwan, with the record date of June 30, 2020.

• TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy

  5/31/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced topline results from the TLC590 Phase II clinical trial, a randomized, double-blind, placebo- and comparator- controlled study of TLC590 in patients following bunionectomy.

• TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

  5/18/2020

  TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

• TLC Reports First Quarter 2020 Financial Results and Provides Business Update

  5/13/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the first quarter ending March 31, 2020, and provided a business update.

• TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a RowTLC is the only listed biotech company to achieve the elite status every year

  5/4/2020

  TLC announced that it has been ranked in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation and Taipei Exchange listed companies in the sixth annual evaluation, becoming the only biotech company to have received this status for six consecutive years.

• TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy

  2/12/2020

  Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020

• TLC Reports Fiscal Year End 2019 Financial Results and Provides Business Update

  2/11/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the fiscal year ended December 31, 2019, and provided a business update.

• TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy

  1/8/2020

  TLC announced that the first batch of patients has been dosed in Part 2 of the Phase II clinical trial for TLC590 in patients following bunionectomy surgery.